Search

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics For Geographic Atrophy, a Leading Cause of Blindness Worldwide

Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Submit Your Partnering Opportunity

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Interview with Norbert Kraut: How cancer drives us forward

Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Transition to renewable energy signals a broader commitment to environmental sustainability

BI Cares PAP portal

Ridgefield Research and Innovation

Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.

Building lasting partnerships for a better future

Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.

Fremont, California

Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Code of Conduct

Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers